Figure 4. NASH resolution was not significantly different
between FGF21 analog and placebo. M-H = Mantel-Haenszel method; CI =
Confidence Interval.
FGF21 therapy led to
substantial reductions in HbA1c levels among patients (MD -0.20; 95% CI
-0.37 to -0.02; p=0.03; I²=22%; Figure S2). In addition, weight loss
was not significantly different between groups (MD -0.33; 95% CI -1.36
to 0.70; p=0.55; I²=9%; Figure S3). However, the rate of adverse events
was significantly higher in the FGF21 analog group in comparison to
placebo (RR 1.08; 95% CI 1.01 to 1.14; p=0.02; I²=0%; Figure 5),
although there was no statistically significant difference in serious
adverse effects between groups (RR 1.05; 95% CI 0.58 to 1.90; p=0.87;
I²=10%; Figure S4).